AroCell AB (publ) announced that a distribution agreement has been signed with the Gongyingshi for the promotion and distribution of the AroCell TK 210 ELISA in China. The pharmaceutical and biotechnological industries are growing rapidly in China making it an attractive market for innovative biomarker assays such the AroCell TK 210 ELISA. TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information about cell proliferation and disruption in patients with cancer tumors. But also, during patient monitoring of cancer treatment, TK 210 ELISA may support clinicians to optimize treatment and estimate the risk of recurrence.